Myriad Genetics, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+60.6% +$4M
$11M
Free Cash Flow↑+60.6% +$4M
$11M
Investing Cash Flow↓-16.9% -$1M
$-8M
Financing Cash Flow
$56M
Capex
—
Acquisitions
—
Stock Buybacks
—
Stock-Based Comp↓-74.3% -$8M
$3M
Debt Issued
—
D&A↓-14.9% -$2M
$13M
SBC Allocated Expense↓-74.3% -$8M
$3M
SBC Unrecognized Cost
—